Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7J5H0)

• Drug Name: SAR444200 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM7J5H0

Molecule-Related Drug Atlas

Drug(s) Targeting Glypican-3 (GPC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7686	DM6CNFW	Hepatocellular carcinoma	2C12.02	Phase 2	[3]
GPC-3298306	DMOHAS2	Hepatocellular carcinoma	2C12.02	Phase 2	[4]
Codrituzumab	DMDWG36	Hepatic metastasis	2D80	Phase 2	[5]
GC33	DMXTD74	Hepatocellular carcinoma	2C12.02	Phase 2	[3]
GPC3-CART cells	DMGN679	Hepatocellular carcinoma	2C12.02	Phase 1/2	[6]
TAI-GPC3-CART cells	DMCFSZ5	Hepatocellular carcinoma	2C12.02	Phase 1/2	[7]
CAR-T cells targeting GPC3	DM6H1MQ	Hepatocellular carcinoma	2C12.02	Phase 1/2	[8]
Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs	DMDO6J1	Hepatocellular carcinoma	2C12.02	Phase 1/2	[9]
CAR-T cells targeting Glypican-3 (GPC3)	DMDSKR2	Hepatocellular carcinoma	2C12.02	Phase 1/2	[10]
GPC3 targeting CAR-T cells	DMVWHS1	Hepatocellular carcinoma	2C12.02	Phase 1	[11]

Drug(s) Targeting T-cell receptor (TCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[5]
RGI-2001	DM4AC2F	Graft-versus-host disease	4B24	Phase 2	[12]
IR502	DMW2IF9	Plaque psoriasis	EA90.0	Phase 2	[13]
TOL-101	DM6AXV9	Multiple sclerosis	8A40	Phase 1/2	[14]
MAGE-A10 TCR	DM6H3YS	Bladder cancer	2C94	Phase 1/2	[5]
NY-ESO-TCR	DMS0L6J	Melanoma	2C30	Phase 1/2	[5]
AFP TCR	DMHBUMZ	Hepatocellular carcinoma	2C12.02	Phase 1	[5]
BPX-701	DMYERSD	Acute myeloid leukaemia	2A60	Phase 1	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glypican-3 (GPC3)	TTJTSX4	GPC3_HUMAN	Not Available	[2]
T-cell receptor (TCR)	TT7AKW1	NOUNIPROTAC	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Sanofi
• [3] First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
• [4] Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
• [7] ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
• [8] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [9] ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
• [10] ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3
• [11] ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
• [12] Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
• [13] WO patent application no. 2004,0677,06, Production of multimeric proteins.
• [14] First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.